Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Humankind Investments LLC

Humankind Investments LLC lifted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,972 shares of the medical research company’s stock after buying an additional 473 shares during the period. Humankind Investments LLC’s holdings in Edwards Lifesciences were worth $516,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Harbor Capital Advisors Inc. lifted its holdings in shares of Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after buying an additional 273 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its position in Edwards Lifesciences by 6.7% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $3,702,000. Avanza Fonder AB purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $4,845,000. Finally, Farmers & Merchants Investments Inc. lifted its stake in shares of Edwards Lifesciences by 21.1% in the 4th quarter. Farmers & Merchants Investments Inc. now owns 134,341 shares of the medical research company’s stock valued at $9,945,000 after purchasing an additional 23,409 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.40, for a total transaction of $837,000.00. Following the completion of the transaction, the chief financial officer now owns 41,098 shares in the company, valued at approximately $3,057,691.20. The trade was a 21.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 89,681 shares of company stock worth $6,492,703. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Evercore ISI reduced their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Truist Financial dropped their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a report on Friday, April 11th. Piper Sandler raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $73.00 to $80.00 in a research note on Thursday, April 24th. Finally, Barclays lifted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $79.45.

Edwards Lifesciences Price Performance

EW opened at $73.82 on Friday. The stock’s 50-day moving average price is $71.48 and its 200 day moving average price is $71.50. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The firm has a market cap of $43.40 billion, a price-to-earnings ratio of 10.59, a PEG ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion for the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the prior year, the company earned $0.66 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.